Repligen Corporation (RGEN): Price and Financial Metrics
RGEN Price/Volume Stats
Current price | $156.91 | 52-week high | $200.98 |
Prev. close | $159.49 | 52-week low | $110.45 |
Day low | $156.06 | Volume | 178,763 |
Day high | $161.00 | Avg. volume | 586,689 |
50-day MA | $149.45 | Dividend yield | N/A |
200-day MA | $160.98 | Market Cap | 8.76B |
RGEN Stock Price Chart Interactive Chart >
RGEN POWR Grades
- RGEN scores best on the Quality dimension, with a Quality rank ahead of 59.56% of US stocks.
- The strongest trend for RGEN is in Growth, which has been heading down over the past 177 days.
- RGEN ranks lowest in Growth; there it ranks in the 2nd percentile.
RGEN Stock Summary
- The price/operating cash flow metric for REPLIGEN CORP is higher than 95.16% of stocks in our set with a positive cash flow.
- Of note is the ratio of REPLIGEN CORP's sales and general administrative expense to its total operating expenses; 98.2% of US stocks have a lower such ratio.
- With a price/sales ratio of 12.3, REPLIGEN CORP has a higher such ratio than 92.44% of stocks in our set.
- Stocks that are quantitatively similar to RGEN, based on their financial statements, market capitalization, and price volatility, are ROG, SLP, NTIC, ALGN, and ATRI.
- Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.repligen.com.
RGEN Valuation Summary
- In comparison to the median Healthcare stock, RGEN's EV/EBIT ratio is 554.82% higher, now standing at 64.5.
- Over the past 243 months, RGEN's price/sales ratio has gone down 4.3.
Below are key valuation metrics over time for RGEN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
RGEN | 2023-11-03 | 12.5 | 4.2 | 72.5 | 64.5 |
RGEN | 2023-11-02 | 11.4 | 3.8 | 65.8 | 58.4 |
RGEN | 2023-11-01 | 11.0 | 3.7 | 63.4 | 56.2 |
RGEN | 2023-10-31 | 11.2 | 3.8 | 64.9 | 57.5 |
RGEN | 2023-10-30 | 8.7 | 3.2 | 46.1 | 38.0 |
RGEN | 2023-10-27 | 9.1 | 3.4 | 48.3 | 39.8 |
RGEN Growth Metrics
- The 5 year net income to common stockholders growth rate now stands at 76.56%.
- Its 4 year net income to common stockholders growth rate is now at 76.56%.
- The 3 year cash and equivalents growth rate now stands at 198.08%.

The table below shows RGEN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 801.536 | 172.083 | 185.959 |
2022-09-30 | 801.295 | 159.821 | 166.34 |
2022-06-30 | 778.77 | 140.937 | 159.433 |
2022-03-31 | 734.097 | 132.867 | 145.805 |
2021-12-31 | 670.534 | 119.016 | 128.291 |
2021-09-30 | 592.661 | 84.267 | 118.879 |
RGEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RGEN has a Quality Grade of C, ranking ahead of 39.46% of graded US stocks.
- RGEN's asset turnover comes in at 0.293 -- ranking 157th of 682 Pharmaceutical Products stocks.
- ORMP, MESO, and AWH are the stocks whose asset turnover ratios are most correlated with RGEN.
The table below shows RGEN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.293 | 0.586 | 0.452 |
2021-06-30 | 0.278 | 0.588 | 0.369 |
2021-03-31 | 0.257 | 0.574 | 0.269 |
2020-12-31 | 0.235 | 0.572 | 0.186 |
2020-09-30 | 0.229 | 0.576 | 0.144 |
2020-06-30 | 0.215 | 0.569 | 0.109 |
RGEN Price Target
For more insight on analysts targets of RGEN, see our RGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $267.88 | Average Broker Recommendation | 1.35 (Strong Buy) |
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
Latest RGEN News From Around the Web
Below are the latest news stories about REPLIGEN CORP that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
Does Repligen Corp. (RGEN) Have a Bright Future?Conestoga Capital Advisors, an asset management company, released its “SMid Cap Growth Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The Conestoga Smid Cap Growth Composite returned -6.36% net of fees in the third quarter, compared to the Russell 2500 Growth Index’s -6.84% return. Stock selection in the Industrials, Health […] |
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability ReportWALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Di |
Repligen Announces Publication of the Company’s 2022 Sustainability ReportWALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Di |
Repligen Corporation to Present at Upcoming Investor ConferencesWALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences. Stifel 2023 Healthcare Conference being held November 14-15 in New York City. Tony J. Hunt, Chief Executive Officer, will participate in an analyst-led discussion on Wednesday, November 15, at 8:00 a.m. ET.Stephens’ Annual Investment Conference being held Novem |
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device- Targeting ADC and Cell & Gene Therapy Customers -WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device. The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal, including antibody drug conju |
RGEN Price Returns
1-mo | 16.61% |
3-mo | -10.71% |
6-mo | -6.19% |
1-year | -12.26% |
3-year | -17.27% |
5-year | 142.63% |
YTD | -7.32% |
2022 | -36.07% |
2021 | 38.20% |
2020 | 107.17% |
2019 | 75.39% |
2018 | 45.37% |
Continue Researching RGEN
Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...